Ftse Mib
33.739,90
-0,08%
DAX
19.848,77
-0,34%
S&P 500
6.040,04
1,10%
NASDAQ
20.031,13
1,35%
Bitcoin
98.356,63
-0,33%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ uniQure NV (QURE) uniQure NV (QURE) Notizie

QURE

uniQure NV (QURE)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:QURE
DataOraFonteTitoloSimboloCompagnia
10/12/202422:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:QUREuniQure NV
10/12/202422:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:QUREuniQure NV
10/12/202413:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:QUREuniQure NV
10/12/202413:05GlobeNewswire Inc.uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s DiseaseNASDAQ:QUREuniQure NV
21/11/202413:05GlobeNewswire Inc.uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe EpilepsyNASDAQ:QUREuniQure NV
14/11/202418:01Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:QUREuniQure NV
05/11/202415:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QUREuniQure NV
05/11/202413:05GlobeNewswire Inc.uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
15/10/202413:05GlobeNewswire Inc.uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALSNASDAQ:QUREuniQure NV
23/09/202413:05GlobeNewswire Inc.uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry DiseaseNASDAQ:QUREuniQure NV
15/08/202413:05GlobeNewswire Inc.uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseNASDAQ:QUREuniQure NV
01/08/202414:54Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:QUREuniQure NV
01/08/202413:05GlobeNewswire Inc.uniQure Announces Second Quarter 2024 Financial Results and Provides Company UpdateNASDAQ:QUREuniQure NV
23/07/202413:05GlobeNewswire Inc.uniQure Announces Closing of Sale of Manufacturing Facility to GenezenNASDAQ:QUREuniQure NV
09/07/202413:05GlobeNewswire Inc.uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s DiseaseNASDAQ:QUREuniQure NV
01/07/202413:05PR Newswire (US)Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MANASDAQ:QUREuniQure NV
01/07/202413:05GlobeNewswire Inc.uniQure Announces Sale of Commercial Manufacturing Facility to GenezenNASDAQ:QUREuniQure NV
03/06/202413:05GlobeNewswire Inc.uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s DiseaseNASDAQ:QUREuniQure NV
07/05/202413:05GlobeNewswire Inc.uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
28/02/202413:05GlobeNewswire Inc.uniQure Announces 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
13/02/202422:33Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:QUREuniQure NV
19/12/202313:05GlobeNewswire Inc.uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s DiseaseNASDAQ:QUREuniQure NV
12/12/202301:30PR Newswire (US)CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia BNASDAQ:QUREuniQure NV
08/12/202313:05GlobeNewswire Inc.uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:QUREuniQure NV
29/11/202313:05GlobeNewswire Inc.uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry DiseaseNASDAQ:QUREuniQure NV
07/11/202313:05GlobeNewswire Inc.uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:QUREuniQure NV
27/10/202316:00PR Newswire (US)CSL and uniQure Win 2023 Prix Galien USA AwardNASDAQ:QUREuniQure NV
26/10/202320:38PR Newswire (Canada)Santé Canada autorise HEMGENIX® de CSL (étranacogène dézaparvovec) comme première thérapie génique pour l'hémophilie BNASDAQ:QUREuniQure NV
26/10/202320:14PR Newswire (Canada)Health Canada Authorizes CSL's HEMGENIX® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia BNASDAQ:QUREuniQure NV
24/10/202313:05GlobeNewswire Inc.uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual MeetingNASDAQ:QUREuniQure NV
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:QURE

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
ENI
Eni
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STMMI
ST Microelectronics
BIT
TIT
Telecom Italia
BIT
LDO
Leonardo
BIT
RACE
Ferrari NV
BIT
PRY
Prysmian
BIT
SPM
Saipem
BIT
BPE
Bper Banca
BIT
CPR
Davide Campari
BIT
AMP
Amplifon
BIT
SRG
Snam
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network